Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Study objective:
1. To evaluate the antihypertensive efficacy, safety and tolerability of the drug after the
oral administration of BR-A-657•K at 20~180mg for 4 weeks to patients with essential
hypertension.
2. To review the pharmacokinetic profile after the multiple administration and the
pharmacodynamic profile regarding the renin-angiotensin system, after the oral
administration of BR-A-657•K at 20~180mg for 4 weeks to patients with essential
hypertension.
3. To determine the dose for the clinical study at the next phase by analyzing the
relationship between the antihypertensive efficacy and pharmacokinetic • pharmacodynamic
results.